Annexin: Attenuating vascular inflammation

Annexin's ANXA5 protein could improve outcomes in peripheral arterial occlusion

Annexin Pharmaceuticals AB is developing an annexin A5 protein to help stop disease progression and prevent limb amputation in peripheral arterial occlusive disease. The protein has therapeutic benefits including anti-inflammatory, antithrombotic and anti-atherosclerotic activity.

Current treatments for peripheral vascular disease (PVD) depend on the cause and severity. These include antithrombotic agents and vasodilators to restore blood flow, and endovascular surgical interventions including stents and balloon angioplasty in occluded vessels.

However, despite surgical interventions and therapeutics, 20% of patients with peripheral

Read the full 784 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE